Every peptide and blend on this site, with the routes and routines the published and community sources mention — each row linked to where it came from, so you can check it yourself. We report what the sources say; we don't invent numbers, and where the research is silent, we say so.
62 of 93 compounds have sourced dosing notes; the rest are listed honestly as not-yet-documented. Companion to the 2026 Reference Guide (the PDF links here).
IV and oral administration (specific dose not specified in text)
Intravenous, Oral
80 mcg
Subcutaneous
16 mg controlled-release subcutaneous implant every two months
Subcutaneous implant
80 mg/day
Inhalation
once a week
Intravenous infusion
80 mg/day
Inhalation
Chronic ip administration for 14 days (specific dose not mentioned in text)
Intraperitoneal (ip)
5 mg BPC-157 + 5 mL BAC water
Subcutaneous, Intramuscular, Intra-articular
Daily
Subcutaneous, Oral
BPC-157 250–500 mcg/day SC + TB-500 2–5 mg twice weekly for 4–6 week loading, then TB-500 2 mg weekly for 4–8 weeks
subcutaneous
Single administration demonstrating effects lasting up to 24 hours
Unspecified
Self-administered injectable medication
Subcutaneous injection
1.75 mg subcutaneous ~45 min before activity
Subcutaneous
2.4 mg each (Cagrilintide 2.4 mg + Semaglutide 2.4 mg)
Subcutaneous, once-weekly
2.4 mg
Subcutaneous injection
Not specified
30 mL in 250 mL physiological saline
Intravenous infusion
CJC-1295: 50-100 mcg; Ipamorelin: 100-200 mcg
Subcutaneous Injection
100 mcg CJC-1295 + 100-200 mcg Ipamorelin
Subcutaneous
Individualized; adjusted according to diurnal pattern of response
Oral (oral syringe)
0.05mg per mL
Oral
At least 1 hour prior to or 2 hours after food
Oral
25 nmol/kg
Intravenous
Injected into the lateral ventricle of cerebrum in rabbits; polygraphic monitoring for 7-12 h daytime
Intracerebroventricular
Intravenous administration on 5 consecutive days followed by 5 injections every 48-72 h
Intravenous
100–500 mcg once daily SC before bedtime
SC
Once a week
Subcutaneous injection
Subcutaneous injection (Dose 1, 2, 3, or 4)
Subcutaneous
1 µg/mouse
Subcutaneous injection
5 mg once daily SC for 20 days, then 4–6 months off-cycle
SC
Twice daily (b.i.d.)
Subcutaneous injection
2 mg
Subcutaneous injection, once weekly
Subcutaneous injection; oral formulation available for semaglutide since 2020
Subcutaneous (oral for semaglutide)
Continuous subcutaneous infusion via osmotic mini-pump
Subcutaneous
Once weekly
Subcutaneous injection
Twice daily
Subcutaneous injection (frequency per article)
Once weekly
Subcutaneous injection (frequency per article)
Twice daily; mean terminal half-life 2.4 h
Subcutaneous
Once weekly
Subcutaneous injection
Single injection
2 mg once weekly
Subcutaneous injection
0.8 mg and 2 mg doses
Subcutaneous injection
0.8 and 2.0 mg, once weekly
Subcutaneous injection
100 nmol/kg i.p.
intraperitoneal (i.p.)
Not specified
Subcutaneous administration
0.1-100 μg/day
Subcutaneous, Intramuscular, Intravenous, Oral
2 μg
Subcutaneous
5 μg
Subcutaneous
100 ng/mouse
Injection (single daily dose for 8 days)
0.1 microgram to 3.0 milligrams per kilogram of patient body weight per day
Systemic (implied)
In vitro (3T3-L1 adipocytes)
In vitro cell culture (3T3-L1 adipocytes)
In Vitro / Cell Culture
Topical application
Topical
Intranasal
Topical
Parenteral (Injection)
50, 100, or 200 nmol/kg
Subcutaneous or Intravenous
Not specified (determined by professional)
Subcutaneous or Intravenous injection
1 to 2 mcg/kg
Subcutaneous / Intravenous
Intranasal
8 weeks on, 8 weeks off
Injection
100 mcg
Subcutaneous
100 mcg
Subcutaneous
100 to 150 mcg
Subcutaneous
1 mcg/kg
Subcutaneous
Acute (45 min) or prolonged (2 days) exposure
In vitro (organ culture)
Oral solid dosage form (tablet core or minitablet with immediate release coating)
Oral
In vitro (isolated rat islets)
Unspecified
Subcutaneous injection
Continuous administration required for efficacy
Subcutaneous injection
Perfused rat pancreas
Perfused pig pancreas
Intraportal infusion
Intraportal
Continuous infusion for 8.5 hrs
intravenous
in vitro (mouse hepatocytes)
75 grams oral glucose
Oral
4.8 pmol/kg/min
Subcutaneous infusion (portable insulin pump)
400 ug
Subcutaneous
50 microg/kg
Injection
200 μg/kg
Intraperitoneal (IP) injection
25 μg kg−1 •hr−1
Intravenous infusion
In vitro (cell culture medium)
Once a week, on the same day each week
Injection under the skin (belly, thigh, upper arm)
Once a day
Subcutaneous (thigh, upper arm, abdominal wall)
Adjusted according to the individual patient’s blood glucose levels
Injection under the skin
0.3 to 1.0 international units (IU) per kilogram body weight per day
Subcutaneous (thigh, abdominal wall, deltoid, gluteal region)
0.5 to 1.0 units per kilogram body weight per day
Subcutaneous
Once a week, on the same day each week. Dose adjusted based on blood glucose levels.
Subcutaneous injection (belly, thigh, or upper arm)
Subcutaneous injection
Individualized dose, injected once or twice a day
Subcutaneous injection (abdominal wall, upper arm, or thigh)
Individualized dose, injected once or twice a day at mealtimes
Subcutaneous injection (abdominal wall, upper arm, or thigh)
Individualized based on blood glucose testing
Subcutaneous injection (belly or upper arm)
0.5 to 1.0 units per kilogram body weight per day
Subcutaneous injection (abdominal wall, thigh, upper arm, shoulder, or buttock)
0.5 to 1.0 units per kilogram body weight per day
Subcutaneous injection
0.3 to 1.0 international units (IU) per kilogram body weight per day
Subcutaneous injection (thigh, abdominal wall, gluteal region, or deltoid region)
100 per 30 days
Topical/Diagnostic
100ml
Subcutaneous injection, Intravenous infusion
Single-dose (Phase 1 PK/Safety study)
Injection
Single subcutaneous dose
Subcutaneous injection
Varies (Long-term treatment)
Subcutaneous injection (every day)
0.25–0.5 units per kilogram of body weight
Subcutaneous injection
daily
Injection
$25 for a single 10 mL vial and $35 for 2 to 4 vials in a month
Subcutaneous/Injection
$35 per 30-day supply
Subcutaneous/Injection
$35 per month supply
Subcutaneous/Injection
$25-per-vial list price
Subcutaneous/Injection
$25 per vial
Subcutaneous/Injection
100–250 mcg once daily SC (research: 100–300 mcg 2–3×/day)
SC
0.3–10 nmol/kg
Intravenous bolus
1.0 nmol/kg
Intravenous bolus
Contains GHK-Cu, BPC-157, TB-500, KPV
500 mcg each of TB-500, BPC-157 and KPV + 2.5 mg GHK-Cu once daily SC (range 250–750 mcg each)
SC
10^-12 M to 10^-3 M (Cosmetic)
Topical
42 mg
Subcutaneous injection
45 mg subcutaneous Q6M, 24 mo
Subcutaneous
Once daily administration
Unspecified
Daily
Injection
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Once-daily, dose adjusted individually
Subcutaneous injection (thigh, upper arm, or abdomen)
3 mg once daily
Subcutaneous injection
0.6 mg daily (Week 1), 1.2 mg daily (Standard), 1.8 mg daily (Max)
Subcutaneous injection
3 mg daily
Subcutaneous injection
Once-daily subcutaneous injection in the abdomen, thigh, or upper arm
Once-daily subcutaneous injection
0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg
Subcutaneous injection (abdomen, thigh, or upper arm)
0.6 mg, 1.2 mg, or 1.8 mg
Subcutaneous injection
Single subcutaneous injection
Subcutaneous
Single subcutaneous injection
Subcutaneous
Subcutaneous injection
Once daily
Subcutaneous injection (frequency per article)
20 micrograms/0.2ml
Injection (Pre-filled disposable device)
10µg for 2 weeks then 20µg for ten weeks
Subcutaneous (implied by injectable solution)
10µg for one week, 15µg for one week, and then 20µg for ten weeks
Subcutaneous (implied by injectable solution)
20µg
Subcutaneous (implied by injectable solution)
10 μM
In vitro (agarose gel/RDM media)
10 μM (above MIC)
In vitro (culture)
10 μM (above-MIC) and 4.0 μM (sub-MIC) in single-cell microscopy experiments
In vitro microscopy under agarose gel
In vitro (E. coli culture)
10 μM applied to E. coli cells under agarose gel containing RDM growth media in single-cell imaging experiments
In vitro (cell culture microscopy)
4.0 μM sub-MIC concentration of dye-tagged peptide in single-cell experiments
In vitro (cell culture microscopy)
14 μM initial AMP concentration incubated with E. coli, followed by centrifugation separation
In vitro (microplate assay)
In vitro culture assay
10 μM (above-MIC) and 4.0 μM (sub-MIC) under agarose gel containing RDM media
Microscopy, in vitro
in vitro broth microdilution (96-well plate)
in vitro, added to rich defined medium (RDM)
Oral
Oral
For a patient weighing 120 kg: Use 2 pouches
Oral
250–1000 mcg once daily SC (loading), then 500–1000 mcg 1–2×/week
SC
62 mg
Subcutaneous
Subcutaneous injection
Intraperitoneal injection (mice)
Injection
Injected via AAV1 (Adeno-Associated Virus) vector
Injection
In vitro (Cell culture)
Oral
30 mg
intramuscularly once every 28 days
Intravenous
Intravenous
Monthly injections
Injection
Not specified
Intramuscular injection
40 mg to 80 mg daily (20 mg twice daily)
Oral
Monthly injections
Injection
1 μg/g-day
Subcutaneous injection
8 × 10^-12 to 2 × 10^-11 M
Ischemic Preconditioning (Rat Heart)
Not specified
Parenteral (clinical administration)
10 ug/kg/hour
Intravenous infusion
1 ug/kg/hour
Intravenous infusion
10 ug/kg/hour
Intravenous
Varies (Requires Titration)
Subcutaneous Injection
three times daily
Subcutaneous
1-10 pM (physiological concentrations)
In vitro / Isolated duct perfusion
0.2 ug/kg over 1 min (after 0.2 ug test dose)
intravenous
intravenous
intravenous
Intraperitoneal injection
Selank: 200–300 mcg; Semax: 200–400 mcg
Intranasal
7–14 mg
Oral
~400 mg
Oral
0.5 mg and 1.0 mg
Subcutaneous injection
Discard vial within 28 days after first use; use a new sterile needle and syringe for each dose
Subcutaneous injection
2.4 mg once weekly subcutaneously
subcutaneous
0.5 mg or 1.0 mg once weekly subcutaneously
subcutaneous
0.25 mg once weekly, escalating to 0.5 mg, 1 mg, 1.7 mg, and maintenance 2.4 mg
Subcutaneous injection
10 μg/kg
Systemic (injection, murine model)
10 μg/kg, administered 120 minutes before oral glucose challenge
Systemic (injection, murine model)
Once daily
Oral
Varies; reports of doses beyond FDA-approved label limits
Injectable
3 mg, 7 mg, or 14 mg orally once daily
oral
Once-weekly subcutaneous injection via prefilled pen; low starting dose increased every 4 weeks for first 16 weeks to reach recommended dose
Subcutaneous (abdomen, upper arm, or thigh)
One tablet once daily on an empty stomach after at least 8 hours fasting; wait 30 minutes before eating, drinking or taking other medicines
Oral
Subcutaneous
Once daily on an empty stomach after at least 8 hours of fasting; wait 30 minutes before eating, drinking, or taking other medicines
Oral
One tablet once daily on an empty stomach after at least 8 hours fasting; wait 30 minutes before eating, drinking or taking other medicines
Oral
2.5 mg to 40 mg co-formulated with 300 mg SNAC
Oral
Manufactured in a variety of dosage strengths; patients typically start at the lowest dosage strength and, as needed, increase dosage strengths over time
Injection
0.25 milligrams (5 units / 0.05 mL) drawn with U-100 insulin syringe
Subcutaneous injection
One tablet once daily on an empty stomach after at least 8 hours of fasting; wait 30 minutes before eating, drinking or taking other medicines
Oral
One tablet once a day on an empty stomach after at least 8 hours of fasting; wait 30 minutes before eating, drinking or taking other medicines
Oral
Subcutaneous
2.4 mg once weekly for weight reduction in patients with BMI ≥30 kg/m² (approved 2021)
Subcutaneous
Once daily on an empty stomach after at least 8 hours of fasting; wait 30 minutes before eating, drinking or taking other medicines
Oral
Subcutaneous
subcutaneous
subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
2.4 mg once weekly
Subcutaneous
7-14 mg semaglutide co-formulated with ~400 mg SNAC, oral
Oral
0.25 mg, 0.5 mg, 0.1 mg once weekly
Subcutaneous
1.7 mg, 2.4 mg once weekly
Subcutaneous
Start low, increase every 4 weeks up to 25 mg
Oral
Maximum dose of 2.4 mg
Injection
Once-weekly injection
Subcutaneous (abdomen, thigh, or upper arm)
3 mg once daily for 30 days, then increase to 7 mg once daily. If blood glucose levels are still too high after another 30 days, provider may increase dose to 14 mg once daily.
Oral
0.25 mg once weekly for the first 4 weeks, then increase to 0.5 mg once weekly. If blood glucose levels are still too high, dose may continue to increase every 4 weeks until reaching the effective amount (up to 2 mg once weekly).
Subcutaneous injection
Up to 120 mL water, fast for 30 min post-dose
Oral
Once-weekly
Subcutaneous
25mg
Oral
3mg to 14mg
Oral
2.4 mg weekly
Injection
25 mg once daily
Oral
Days 31 through 60
Oral
Days 61 through 90
Oral
Initiate 25 mg maintenance dosage
Oral
Filled prescription within 180 days of bariatric surgery
Unknown
0.5-100 mg (including ranges of 0.5-50 mg, 0.5-25mg, 1-25 mg, 5-50 mg, 0.5-10 mg, 0.5-5 mg)
Oral
25mg daily
oral
Subcutaneous injection
0.1-50 mg
Oral
Up to 2.4 mg weekly
Subcutaneous Injection
Up to 2 mg weekly
Subcutaneous Injection
Up to 2.4 mg once weekly
Subcutaneous Injection
Once weekly
Subcutaneous Injection
Start at lowest dose, then increase gradually to match equivalent of previous compounded semaglutide dose
Injection
First dose of second drug administered seven days after discontinuation
Injection
First dose of second drug administered one day after discontinuation
Injection
Both are semaglutide, but their FDA-approved uses and recommended dosages differ
Not specified
Single dose of 10 mg semaglutide with 300 mg SNAC
Oral
Once-daily oral tablet, started at a low dose and increased about every four weeks to a maximum of 25 mg; taken first thing in the morning on an empty stomach with only 4 ounces of water, then wait 30 minutes before eating, drinking, or taking other medications; tablet must be swallowed whole
Oral
0.5mg and 1mg
Subcutaneous
up to 2.4mg (maintenance)
Subcutaneous
25 mg once daily, with 12-week dose escalation
Oral
Injection
2.4 mg once weekly subcutaneous injection, with reduced-calorie diet and increased physical activity
Subcutaneous injection
0.1-50 mg GLP-1 agonist per composition
Oral
First dose administered seven days after discontinuation
Subcutaneous injection
First dose administered one day after discontinuation
Subcutaneous injection
Used in clinical trials for up to 104 weeks (2 years); intended for long-term use
Not specified in text
25mg daily (oral), under FDA review
Oral
3mg initiation, advanced to 7mg, then 14mg maintenance
Oral
1 mg injected once weekly
Subcutaneous injection
2.4 mg weekly
Injection
2.4 mg injection, used alongside a low-calorie diet and increased physical activity
Subcutaneous injection
3 mg, 7 mg, 14 mg titration
Oral
1.5 mg, escalate to 4 mg at day 31, escalate to 9 mg at day 61 if additional glycemic control required
Oral
At least three 0.25 mg doses spanning at least six months
Subcutaneous injection
0.5mg and 1mg lower doses for type 2 diabetes
Subcutaneous
Switch to 1.7 mg Wegovy injection with dosage escalation schedule
Subcutaneous
2.4 mg injection
Subcutaneous injection
At least three 0.25 mg doses spanning at least six months
subcutaneous injection
50 mg daily, on an empty stomach with a water-only window
Oral
At least three 0.25 mg doses spanning at least six months
Subcutaneous injection
Patients can switch between Rybelsus formulations after 30 days; can switch from Ozempic to Rybelsus 1 week after discontinuation
Oral
No dose adjustment needed; same recommended dosage for patients with and without renal impairment
Oral
At least three 0.25 mg doses spanning at least six months (study definition)
Subcutaneous injection
2.4 mg weekly
Subcutaneous injection
At least three 0.25 mg doses spanning at least six months
Subcutaneous injection
0.5-100 mg (e.g. 0.5-25 mg, 1-25 mg), administered every second day or more often, e.g. once or twice daily
oral
$350 per month via TrumpRx under US pricing agreement
subcutaneous injection
$49 for the first month, $99 per month thereafter
Oral
7.2 mg
Subcutaneous injection
25 mg
Oral
0.5 mg, 1 mg, or 2 mg
Subcutaneous injection
4 mg or 9 mg
Oral
25 mg and 50 mg vs 14 mg
Oral
0.25 mg weekly (Weeks 1-4), 0.5 mg weekly (Weeks 5-8), 1.0 mg weekly (Week 9+)
Subcutaneous
0.25 mg (Weeks 1-4) -> 0.5 mg (Weeks 5-8) -> 1.0 mg (Weeks 9-12) -> 1.7 mg (Weeks 13-16) -> 2.4 mg (Week 17+)
Subcutaneous Injection
1.5 mg (4 weeks) -> 4 mg (4 weeks) -> 9 mg (4 weeks) -> 25 mg (maintenance)
Oral
1 mg titrated to 2 mg subcutaneous semaglutide
Subcutaneous
2.4 mg cagrilintide / 2.4 mg semaglutide weekly, escalated in parallel over 16-20 weeks
Subcutaneous
0.5-100 mg (e.g. 0.5-50 mg, 1-25 mg, 5-50 mg) administered every second day or more often (e.g. once or twice daily), oral tablet
Oral
Subcutaneous
Subcutaneous injection
Subcutaneous (product labeling)
Aqueous injectable solution at pH between 5.0 and 6.0
Subcutaneous injection (injectable composition)
Not specified in sources
Injection
200-900 mcg/day
Intranasal
3,000-9,000 mcg/day
Intranasal
200-600 mcg daily
Intranasal
2 to 3 drops per nostril, 2 to 3 times daily (200 to 900 mcg/day)
Intranasal
3,000 to 9,000 mcg daily
Intranasal
200–500 mcg once daily SC (intranasal: 600–1500 mcg/day)
SC
0.2 - 0.3 mg once daily at bedtime
Subcutaneous injection
500/500 mcg increasing to 1,000/1,000 mcg
Subcutaneous at bedtime
Sermorelin 200 to 300 mcg plus ipamorelin 200 to 300 mcg
Injection
Not specified
Injection
Radiolabelled somatostatin analogue administered for imaging
Diagnostic administration
100 nmol/l
Perfusion / In vitro (Islet stimulation)
Not specified (implied injection/administration)
Highest dose (specific mg not provided)
Injectable (weekly)
Subcutaneous injection
Subcutaneous
20μg
Subcutaneous injection
11.6MG
Subcutaneous
1MG
Subcutaneous
2MG
Subcutaneous
Tesamorelin 1–1.4 mg + Ipamorelin 100–200 mcg
Subcutaneous
1.6 mg (900 µg/m²) subcutaneously twice a week for 6 to 12 months
Subcutaneous
Up to 15 mg
Subcutaneous injection
Once weekly subcutaneous injection
Subcutaneous
Once weekly injection under the skin
Subcutaneous
Injected once weekly
Subcutaneous injection
36-week trial duration
Unspecified
Once weekly injection
Subcutaneous
2.5 mg doses spanning at least six months
Subcutaneous injection
2.5 mg doses spanning at least six months
subcutaneous injection
2.5 mg doses spanning at least six months
Subcutaneous injection
2.5 mg doses spanning at least six months (study definition)
Subcutaneous injection
2.5 mg doses spanning at least six months
Subcutaneous injection
2.5 mg doses spanning at least six months
Subcutaneous injection
2.5 mg doses spanning at least six months
Subcutaneous injection
Once-weekly subcutaneous dosing
Subcutaneous
10 mg or 15 mg
Subcutaneous injection
Subcutaneous (product labeling)
Intranasal treatment (specific dosage not provided)
Intranasal
50 or 100 µg
Intraperitoneal
1 µg
Central injection (into the brain)
These compounds are in our library, but the sources we've collected don't include dosing details. When a sourced note exists, it appears above — never a guess.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.